Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plerixafor - Sanofi

Next Previous
Drug Profile

Plerixafor - Sanofi

Alternative Names: AMD 3100; JM 3100; LM-3100; Mozobil; Plerixafor-hydrochloride; SDZ SID 791

Latest Information Update: 09 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Corporation; Rega Institute for Medical Research
  • Developer Dana-Farber Cancer Institute; Memorial Sloan-Kettering Cancer Center; Sanofi
  • Class Anti-ischaemics; Antianaemics; Antineoplastics; Antiretrovirals; Antirheumatics; Heterocyclic compounds; Polyamines; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stem cell mobilisation
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Stem cell mobilisation
  • Phase II Glioma
  • Phase I/II Acute myeloid leukaemia; Multiple myeloma
  • No development reported Chronic lymphocytic leukaemia; Colorectal cancer; Myocardial infarction; Ovarian cancer; Pancreatic cancer; Sickle cell anaemia
  • Discontinued HIV infections; Rheumatoid arthritis

Most Recent Events

  • 27 Mar 2025 Memorial Sloan Kettering Cancer Center completes a phase-I clinical trials in Sickle cell anaemia in USA (SC) (NCT02193191)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Pancreatic-cancer(Late-stage disease, Second-line therapy or greater) in United Kingdom (IV, Infusion)
  • 08 Feb 2024 Stanford University in collaboration with Sanofi completes a phase II trial in Glioma (Combination therapy, Late-stage disease, First-line therapy) in USA (IV) (NCT03746080)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top